Amgen Inc. (AMGN) announced on Friday that the U.S. Food and Drug Administration has approved its Lumakras combined with Vectibix for use in treating patients with KRAS G12C-mutated metastatic colorectal cancer. This approval follows the pivotal Phase 3 CodeBreaK 300 study, which demonstrated that this combination therapy offers better progression-free survival compared to standard treatments.
In the study, Lumakras was tested at doses of 960 mg and 240 mg in combination with Vectibix against the investigator's selected standard treatments, which included trifluridine/tipiracil or regorafenib. Amgen highlighted that the combination therapy also achieved its secondary goals, which included improved overall survival and response rates among participants.
Currently, Amgen's shares are trading at $272.83 on the Nasdaq, reflecting a 1.26 percent increase.
